Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 253

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Anti–Aquaporin‐4 monoclonal antibody blocker therapy for neuromyelitis optica

Open access
Tradtrantip, Lukmanee, Zhang, Hua, Saadoun, Samira, Phuan, Puay‐Wah, Lam, Chiwah, Papadopoulos, Marios C., Bennett, Jeffrey L., Verkman, A. S. · 2012 · Annals of Neurology

Abstract

Objective: Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system. Circulating autoantibodies (NMO‐immunoglobulin [Ig]G) against astrocyte water channel aquaporin‐4 (AQP4) cause complement‐ and cell‐mediated astrocyte damage with consequent neuroinflammation and demyelination. Current NMO therapies, which have limited efficacy, include immunosuppression and plasma exchange. The objective of this study was to develop a potential new NMO therapy based on blocking of pathogenic NMO‐IgG binding to its target, AQP4. Methods: We generated nonpathogenic recombinant monoclonal anti‐AQP4 antibodies that selectively block NMO‐IgG binding to AQP4. These antibodies comprise a tight‐binding anti‐AQP4 Fab and a mutated Fc that lacks functionality for complement‐ and cell‐mediated cytotoxicity. The efficacy of the blocking antibodies was studied using cell culture, spinal cord slice, and in vivo mouse models of NMO. Results: In AQP4‐expressing cell cultures, the nonpathogenic competing antibodies blocked binding of NMO‐IgG in human sera, reducing to near zero complement‐ and cell‐mediated cytotoxicity. The antibodies prevented the development of NMO lesions in an ex vivo spinal cord slice model of NMO and in an in vivo mouse model, without causing cytotoxicity. Interpretation: Our results provide proof of concept for a therapy of NMO with blocking antibodies. The broad efficacy of antibody inhibition is likely due to steric competition because of its large physical size compared to AQP4. Blocker therapy to prevent binding of pathogenic autoantibodies to their targets may be useful for treatment of other autoimmune diseases as well. ANN NEUROL 2012;

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.22657

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 253

Metadata

Authors
Tradtrantip, L., Zhang, H., Saadoun, S., Phuan, P., Lam, C., Papadopoulos, M. C., Bennett, J. L., & Verkman, A. S.
Venue
Annals of Neurology
Publisher
Wiley
Published
2012-01-23
Volume
71
Issue
3
Pages
314-322
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W2171013521
Cited by
253
References
38
FWCI
18.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.